EGFR and neoplasm: As an alternative to full-size antibodies, we have previously investigated the smaller, IR700-labelled EGFR-specific affibody molecule (ZEGFR:03115-IR700), aiming for more effective tumour penetration, faster delivery, and clearance from non-targeted tissues [22].